Introduction
In 2026, expedited approvals—including FDA priority reviews, accelerated pathways based on surrogate endpoints, and the Commissioner's National Priority Voucher (CNPV) program—have radically transformed the pharmaceutical market by reducing drug development cycles, accelerating patient access to breakthrough treatments, and shifting competitive dynamics towards speed and innovation, particularly in obesity, neurology, and rare disease sectors.
What are Expedited Designations
Expedited designations are FDA programs created to accelerate the development and review of drugs intended for serious diseases with unmet medical needs. These routes—such as Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review—provide benefits like more frequent FDA engagement, rolling submissions, and reduced review timelines to help deliver important treatments to patients sooner.
